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Abstract
Introduction: Crohn’s disease is a chronic inflammatory bowel disease of unknown etiology which may affect any
part of the bowel. Fistulas are a common and often serious complication of Crohn’s disease. The treatment for
fistulizing Crohn’s disease can be medical, surgical or a combination of the two. Recently, adalimumab, a fully
human anti-tumor necrosis factor monoclonal antibody, has been suggested as a safe and effective treatment for
the induction and maintenance of remission in adult patients with moderate to severe Crohn’s disease, who are
refractory to conventional therapy or intolerant to infliximab. However, large studies focusing on evaluating the
efficacy of adalimumab in fistulizing Crohn’s disease have not yet been published.
Case presentation: We report the cases of three patients, of European Caucasian ethnicity and Greek nationality,
with active luminal and fistulizing Crohn’s disease. All of the cases were treated successfully with adalimumab.
Patient 1 (a 44-year-old man) and patient 2 (an 18-year-old woman) developed early post-surgical enterocutaneous
fistulas, while patient 3 (a 20-year-old woman) had peri-anal fistulizing Crohn’s disease. Adalimumab treatment (160
mg subcutaneously at week zero, 80 mg at week two, and 40 mg every other week) was used for three different
indications: (1) after the failure of other conservative medical treatments for Crohn’s disease (patient 1); (2) as a
monotherapy in treating a naive patient (patient 2); (3) after an intolerance to infliximab (patient 3). A remission of
the active luminal and fistulizing disease was achieved soon after the initiation of adalimumab and sustained
thereafter with maintenance doses. No further surgical intervention was required and no adverse effects were
observed in any of the cases.
Conclusions: Fistulizing Crohn’s disease remains a challenge in clinical practice. Adalimumab seems to be an
effective, well-tolerated and safe treatment option for the induction and maintenance of remission in patients with
moderate to severe peri-anal fistulizing Crohn’s disease. Furthermore, adalimumab seems to be a promising
treatment option for patients with moderate to severe fistulizing Crohn’s disease with enterocutaneous fistulas.
However, this clinical observation needs to be investigated in further clinical trials.
Introduction
Crohn’s disease (CD) is a granulomatous, segmental,
transmural inflammation of unknown etiology, affecting
the bowel and predisposing the formation of strictures,
perforation, abscesses and fistulas. Fistulas occur in 30
to 50 percent of CD patients during the course of
disease. Peri-anal fistulas are the most common type (50
percent), followed by internal enteroenteric fistulas (25
percent) [1].
The treatment for fistulizing Crohn’sd i s e a s e( F C D )
can be medical, surgical or a combination of the two.
Various medical therapies, including antibiotics, immu-
nomodulators (azathioprine, 6-mercaptopurine, cyclos-
porine) and total parenteral nutrition (TPN), have been
used to treat FCD and have been effective to some
degree. It is well-known that inflammation in CD is
associated with high levels of tissue tumor necrosis
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against this cytokine have recently become the focus of
interest. Infliximab, a chimeric (75 percent human and
25 percent murine) immunoglobulin G1(IgG1)m o n o c l o -
nal antibody against TNF-a, is the prototype anti-TNF-a
agent shown to be efficacious in both the induction and
maintenance of fistula closure in approximately two-
thirds of patients and has now become the cornerstone
of medical therapy for FCD [2]. However, some patients
with FCD are refractory or intolerant to this agent.
Recently, adalimumab (D2E7/Humira
®, Abbott Labora-
tories), a fully humanized, subcutaneously-delivered
immunoglobulin G1(IgG1) monoclonal antibody, which
binds with high affinity and specificity to TNF but not
to lymphotoxin, has been proven to be a safe and effec-
tive treatment for the induction and maintenance of
remission in adult patients with moderate to severe CD
(luminal and/or fistulizing), who are refractory to con-
ventional therapy or intolerant to infliximab [3-5].
In the ACCENT II trial, Sands et al. evaluated and
proved the efficacy of infliximab as a maintenance ther-
apy for CD patients with fistulas [2]. Although previous
studies which evaluated adalimumab included patients
with FCD [3-5], there is one study published by Hino-
josa et al. that clearly demonstrates the efficacy of adali-
mumab treatment in patients with luminal and/or FCD
[6]. There is also published data about the efficacy of
anti-TNF therapy, including adalimumab, in the sub-
group of patients with peri-anal FCD [7,8].
In this case series, we describe our experience with
adalimumab in the treatment of three adult patients
with FCD that resulted in rapid fistula closure and sus-
tained luminal disease remission.
Case presentation
We report the cases of three patients, of European Cau-
casian ethnicity and Greek nationality, with active lumi-
nal and FCD.
Patient 1
A 44-year-old man with a small bowel obstruction
(SBO) underwent a laparotomy which revealed a stenos-
ing, edematous small bowel segment near a former ana-
stomosis. A total of 50 cm of his small bowel was
resected. He had previously undergone an extensive sur-
gical resection of the ileum for SBO. Both histologic
examinations were suggestive of ischemic enteritis.
One week later, post-operative enterocutaneous fistu-
las (ECF) developed next to the drainage catheters origi-
nating from the anastomosis site. We administered TPN
and antibiotics (ciprofloxacin 1000 mg/day and metroni-
dazole 1500 mg/day for two weeks). One month later,
the fistulas were still active, with draining of fecal-muco-
purulent discharge as a byproduct of the fistulas daily
upon oral feeding. An endoscopic examination revealed
linear, deep ulcers with edematous margins in his
ascending colon, cecum, ileocecal valve and terminal
ileum. A histologic examination revealed a mild
derangement of the enteric crypts architecture, moder-
ate inflammatory focal cryptitis, neutrophilic and eosino-
philic infiltration, and glandular abscesses without
mucus. The findings were consistent with the diagnosis
of CD and treatment with adalimumab subcutaneous
injections was initiated (160 mg at week zero, 80 mg at
week two, and 40 mg every other week). Drainage from
all fistulas was stopped one week after the first dose,
while a complete closure of the fistulas was achieved at
week six and complete remission of the mucosal lesions
was observed in an endoscopy after 14 weeks of treat-
ment. He is currently in remission. This is maintained
with adalimumab monotherapy at 40 mg subcutaneously
every other week, without any adverse effects.
Patient 2
An 18-year-old woman presenting with fever (38.2°C)
and localized right lower quadrant pain underwent sur-
gery for acute appendicitis. During a laparotomy, severe
inflammation of her cecum and terminal ileum was
observed, but only an appendicectomy was performed.
Ten days later, a post-operative fistula developed at the
surgical wound with a fecal-purulent discharge. A colo-
noscopy revealed linear ulcers in her ileum and ascend-
ing colon. A histologic examination revealed focal
ulceration of the surface epithelium, derangement of the
architecture of enteric crypts, severe cryptitis, and a
moderate inflammatory infiltration of the lamina propria
with neutrophil leucocytes, lymphocytes, plasma cells
and eosinophils and epithelioid granulomas. She was
treated with adalimumab monotherapy at a dosage of
160 mg at week zero, 80 mg at week two, and 40 mg
every other week. Two weeks after the third injection,
(in the sixth week of treatment) the fistula was comple-
tely healed, while an endoscopy showed healing of the
gastrointestinal ulcers and luminal disease remission.
She is currently undergoing maintenance treatment with
adalimumab at 40 mg every other week.
Patient 3
A 20-year-old woman was referred to our endoscopy
unit with five peri-anal fistulizing ducts which had
developed during a two-year course of fever and bloody
diarrhea. A colonoscopy revealed linear ulcers in her
terminal ileum, cecum and ascending colon. A histologic
examination of the biopsy samples showed mucosal sur-
face erosions and dense inflammatory cellular infiltra-
tions of lymphocytes, plasma cells, eosinophils and
neutrophil leucocytes in the lamina propria extending to
the muscularis mucosa and crypt abscesses. A diagnosis
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Index (CDAI) score of 320 and a Peri-anal Disease
Activity Index (PDAI) score of 14. An examination
under anesthesia revealed complex peri-anal disease and
non-cutting drainage setons were inserted in the fistula
tracks. Consequently, she was treated with mesalamine
(3.2 g/d), oral prednisolone (1 mg/kg) with a tapering
schedule, metronidazole (1500 mg/d for 10 days) and
ciprofloxacin (1000 mg/d for one month). Three months
later, there had been no significant improvement and
she continued to require high doses of prednisolone (20
mg/d). A steroid-sparing treatment with azathioprine
(100 mg/day) and later with methotrexate (15 mg/wk)
failed because of serious drug-induced adverse effects;
she developed pancreatitis after six weeks of azathiopr-
ine and hepatitis after three weeks of methotrexate.
Finally, infliximab (5 mg/kg at weeks zero, two, and six,
and then every eight weeks) was administered and
resulted in the closure of two of five draining fistula
ducts (PDAI score: 7). Unfortunately, during the sixth
injection (in the 30th week of treatment), she developed
severe acute laryngismus with hoarseness, dyspnea, cya-
nosis and tachycardia. The infliximab treatment was dis-
continued. Four weeks later, an endoscopic evaluation
showed a recurrence of active luminal CD, while the
peri-anal disease had not deteriorated (PDAI score: 7).
Treatment with per-oral prednisolone (1 mg/kg) was
administered in combination with adalimumab subcuta-
neous injections at a dosage of 160 mg at week zero,
80 mg at week two and 40 mg every other week. This
combination of treatment resulted in a complete closure
of the fistulas after seven weeks (PDAI score: 0) and
complete remission of luminal CD (CDAI score: 132).
Subsequently, the corticosteroids were discontinued
while adalimumab was continued as a maintenance
treatment at a dose of 40 mg every other week. She has
experienced complete fistula closure for the last
18 months without any adverse effects.
Discussion
Our case report describes the cases of three patients
with both active luminal and FCD who were treated
successfully with adalimumab (Table 1). Patient 3, had
severe peri-anal FCD, while patients 1 and 2 developed
post-operative ECF. In the latter two cases, the develop-
ment of fistulas was the reason for further endoscopic
investigation and the final diagnosis of CD.
In patients 1 and 2, adalimumab treatment was used
for three different indications: (1) the failure of other
conservative medical treatments for CD (patient 1); as
monotherapy in treating a naive patient (patient 2); fol-
lowing an intolerance to infliximab (patient 3). Treat-
ment with adalimumab was proven to be efficacious and
safe in all of the three cases.
Remission of active luminal and fistulizing disease was
achieved soon after the initiation of adalimumab and
sustained thereafter with maintenance doses of adalimu-
mab. No further surgical intervention was necessary and
no adverse effects were observed in any of the cases.
The treatment of fistulas, which complicate CD in up
to 40 percent of cases, has greatly evolved in the last 15
years, mainly because of improvements in medical ther-
apy including immunomodulators (azathioprine, metho-
trexate) and biologics (infliximab, adalimumab) [7,8].
The advent of immunomodulators and, later, anti-TNF-
a agents has positioned conservative medical therapy as
the first-line treatment for CD fistulas, with surgery
reserved for refractory or complicated cases. Several
published studies show that TNF-a antagonists (anti-
TNF-a) are effective in inducing and maintaining disease
remission in patients with CD. Infliximab has been
shown to be effective for the treatment of FCD in adult
patients with peri-anal fistulas. Infliximab has even been
s h o w nt os u s t a i nar e s p o n s ei np a t i e n t sw h oh a da n
initial clinical response with fistulas closure to induction
therapy [7,8].
The ACCENT II trial assessed the efficacy of inflixi-
mab maintenance therapy in adult patients with CD
who had at least one draining abdominal or peri-anal
fistula over a period of at least three months [2]. All
patients received an induction dose of 5 mg/kg in weeks
zero, two, and six and afterwards they were randomized
to either a placebo or infliximab maintenance therapy (5
mg/kg every eight weeks) for a total of 54 weeks. The
data indicated that a maintenance treatment with inflixi-
mab was superior to the placebo in patients who
responded to infliximab induction therapy at weeks
z e r o ,t w oa n ds i x .A tw e e k5 4 ,1 9p e r c e n to fp a t i e n t s
receiving the placebo had complete fistula closure com-
pared with 36 percent of patients in the infliximab
maintenance group (p = 0.009). More recently, adalimu-
mab, another TNF-a antagonist, has been approved in
the US and EU for the treatment of CD. Clinical trials
have demonstrated that adalimumab is both effective for
the induction and maintenance of remission in patients
with moderate to severe CD, and safe and efficacious in
regaining a medical response in patients intolerant or
non-responsive to infliximab [3-5,7,8].
In the CHARM trial, the primary objective was to
assess the benefit of two adalimumab dosing regimens -
40 mg every other week and weekly - in maintaining
clinical remission at 26 and 56 weeks in patients with
moderate to severe CD. Overall efficacy in fistula clo-
sure was also assessed, with significant effects of adali-
mumab on fistula closure observed at 26 and 56 weeks.
Complete fistula closure was observed more frequently
among patients treated with adalimumab than those
who were receiving a placebo: 30 percent and 13
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cent and 13 percent, respectively, at week 56 (p =
0.016). At week 56, fistula closure was maintained in
100 percent of patients who had complete fistula closure
at week 26 [4,8].
Hinojosa et al. also evaluated adalimumab in a sub-set
of 22 patients with FCD who lost response to or could
not tolerate infliximab. After adalimumab induction
therapy with 160 mg at week zero and 80 mg at week
two, 23 percent of patients experienced fistula remission
and 41 percent experienced fistula improvement at week
four [6]. In addition, adalimumab has been reported as
an effective and safe treatment in a pediatric CD patient
with severe refractory luminal and fistulizing disease [9].
Recently-reported data from an extension of the
CHARM trial includes a description and analysis of the
demographics, disease characteristics and outcome in
the sub-group of patients with fistulas treated with ada-
limumab, along with an evaluation of the two-year
maintenance of fistula closure during treatment with
adalimumab (ADHERE trial) [7]. This analysis has
shown that adalimumab therapy was associated with
progressive increases in fistula closure over time, with
statistically significant differences between the placebo
and adalimumab groups (p < 0,05) which were first
observed at 16 weeks (15 percent in the placebo group
versus 36 percent in the adalimumab group) [7]. For all
randomly-assigned patients,t h e r ew a sas i g n i f i c a n t
decrease in the mean number of draining fistulas per
day among patients treated with adalimumab by com-
parison with patients treated with a placebo during the
double-blind treatment period (0,88 for the adalimumab
group versus 1,34 for the placebo group; p = 0,002).
Approximately 60 percent of the patients with FCD who
were treated with adalimumab had healed fistulas after
two years of therapy, while 90 percent of patients with
healed fistulas at the end of the CHARM trial main-
tained closure following one additional year of treatment
in the ADHERE trial [7]. The effect of adalimumab on
the number of draining fistulas in each sub-group
(based on immunosuppressants, antibiotics or previous
TNF antagonists experience) was similar to that
observed for the placebo and adalimumab groups [7].
This recent data shows that adalimumab therapy for
FCD resulted in a significant and complete healing of
draining fistulas, with a safety profile consistent with
previous studies on patients with active CD [8].
Adalimumab is also a well-tolerated treatment for CD
in patients who are infliximab naive and for those who
do not respond to or are intolerant of infliximab [4,5,7].
In patients treated with adalimumab, reactions at the
injection site are the most common adverse effects,
while large series show low rates of serious adverse
effects similar to a placebo [4,5,7,8]. Adalimumab also
offers the benefits of decreased immunogenicity and the
ease of subcutaneous administration. Data from the
CLASSIC II trial demonstrated that the percentage of
patients developing antibodies to adalimumab was low
(2.6 percent) [5].
In the case of patient 3, adalimumab therapy resulted
in complete disease remission and the closure of peri-
anal fistulas. This fistula healing was maintained for 18
months without adverse effects.
Although adalimumab has been evaluated for its efficacy
in the healing of peri-anal fistulas in active CD, there is, as
yet, no published data on the use of adalimumab in
patients with ECF. In general, patients with inflammatory
bowel disease represent a high-risk group for the forma-
tion of ECF, as a result of both the process of their disease
and the need for multiple surgeries [10-12].
ECF are one of the most complex and challenging
complications encountered in surgical practice. The
Table 1 Demographic and clinical details of patients treated with adalimumab
Number Case Luminal
+ FCD
Fistula type Previous failed and/or intolerant
therapies
Current treatment Adverse
effects
Treatment
outcome
1 44, M ileo-
colonic CD
Yes Enterocutaneous,
post-operative
Parenteral nutrition Antibiotics -
ciprofloxacine and metronidazole
Adalimumab
monotherapy [160-
80-40]
no Luminal
disease
remission
Fistula
healing
3 20, F ileo-
colonic CD
peri-anal
disease
Yes Peri-anal Corticosteroid resistant Antibiotics -
ciprofloxacine and metronidazole
Azathioprine (fever and pancreatitis)
Methotrexate (hepatitis) Reaction to
infliximab (laryngismus)
Corticosteroids
(tapered off) plus
Adalimumab [160-
80-40] Seton
drainage
no Luminal
disease
remission
Fistula
healing
2 18, F ileo-
colonic CD
Yes Enterocutaneous,
post-operative
No Adalimumab
monotherapy [160-
80-40]
no Luminal
disease
remission
Fistula
healing
CD: Crohn’s disease; M: male; F: female.
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in origin, while spontaneous fistulas account for 15 to
25 percent of all ECF [12-14]. Due to several advances
in medical treatment, the rates of spontaneous fistula
closure have improved significantly, while mortality
remains high, ranging between 5 and 25 percent [15].
The current management of ECF includes controlling
sepsis, optimization of the nutritional state, wound care,
assessment of the fistula anatomy, and the timing of
surgery and surgical strategy (the SOWATS guideline),
with priority given to sepsis treatment and restoration
of the nutritional state [12-15]. Independent variables
examined in reported studies, which are essential in pro-
moting the spontaneous closure of ECF, include control
of malnutrition, hydroelectrolytic imbalance, serum
albumin and elimination of sepsis [14]. In addition, it is
generally recommended that patients do not undergo
restorative surgery in the three to six month period
after the development of ECF [12-15]. Earlier studies
also report that the spontaneous closure of ECF is less
common in fistulas caused by malignancy or CD and is
predominantly seen in colonic ECF, in low-output ECF
and in patients with a closed abdomen [13,14]. More-
over, the probability and timing of a spontaneous clo-
sure of post-operative ECF is related to the location of
the fistula, the site of origin, the output during 24 hours,
the type of post-operative ECF and the fistulous tract.
Overall, small bowel post-operative ECF have a lower
chance of spontaneous closure (~30 percent) compared
to colonic fistulas (~85 percent), while jejunal fistulas
have a higher rate (~40 percent) compared to ileal fistulas
(~25 percent). Multiple post-operative ECF, and those
with a complex fistulous tract and high output (>500 ml/
24 hours), have a low rate of spontaneous closure (3 and
2,5 times higher versus single and low-output post-opera-
tive ECF, respectively). Due to these multiple variables,
the rates of spontaneous closure of post-operative ECF
vary (17 to 71 percent) (Table 2) [12-14].
In our case report, we describe the cases of two
patients who developed post-operative ECF refractory to
classical management with TPN, antibiotics, octreotide
and wound care. The sites of origin were the small
bowel (patient 1) and the cecum (patient 2) and there
were simple fistulous tracts in both cases. Further inves-
tigation led to a diagnosis of active CD and treatment
with a TNF-a antagonist was initiated. Both patients
received adalimumab. We achieved a remission of the
disease and a complete spontaneous closure of the post-
operative ECF in both cases.
Conclusions
The results from a meta-analysis by Peyrin-Biroulet et
al. demonstrate that anti-TNF therapy is safe and effec-
tive for both luminal and FCD, in patients who are
refractory to standard medical therapy. Due to the small
sample size of these drugs, it was not possible to per-
form a sub-group analysis or a direct comparison
between anti-TNF agents, however, in an overall analy-
sis, anti-TNF therapy was more effective than a placebo
for fistula healing in FCD. The above, more detailed,
analysis elevated the results from the ACCENT II study
on the safety and efficacy of infliximab in inducing and
maintaining fistula closure [8]. The CHARM trial, and
more recently the study by Colombel et al. regarding
the ADHERE study, showed that adalimumab therapy
results in the significant and complete healing of drain-
ing fistulas in active FCD. Furthermore, the long-term
healing of draining fistulas was maintained over two
years from the baseline of the CHARM study, while in
the fistula cohort there were no differences in the rate
of adverse effects in patients who received adalimumab
compared to those who received a placebo [7].
The presence of active inflammation as a result of CD,
following on from or without surgery, predisposes to fis-
tulation. An early diagnosis of ECF, the resuscitation of
the patient, the provision of nutritional support and the
control of sepsis have decreased morbidity and mortality
rates and often result in a spontaneous closure of fistu-
las. Definitive surgical management should be performed
only after the restitution of normal physiology and
nutritional improvement; usually after at least six
months, but often over a longer period [12-15].
Table 2 Treatment management of ECF and outcomes
Treatment ECF outcome
SOWATS treatment guideline
(medical + surgical treatment)
Mortality: 10-30%
Fistula closure: ~87,4%
Medical treatment
Alimentary tract rest
Restoration of circulating volume
Restoration of hydroelectrolytic balance
Nutritional support (optimal TPN)
(fistula closure rate: 89-92,3%)
Controlling sepsis
Wound care
Mortality: 5-25%
Spontaneous closure:
17-71%
Restorative surgery
Minimal period: >6 weeks
Mortality: 9,6%-10,8%
(sepsis-related death:
~15,1%)
Surgical closure:
52-90,7%
Persisting fistula: 3-50%
Definitive surgery
Minimal period: >6 months
(median period: 8 months)
Small bowel ECF Mortality: ~35%
Spontaneous closure:
~30%
Colonic ECF Mortality: ~22%
Spontaneous closure:
~85%
References: [12-15].
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adalimumab therapy in patients with moderate to severe
FCD. Although our case series cannot safely propose a
treatment approach, our secondary aim was to report on
both the spontaneous closure of post-operative ECF with
adalimumab therapy in patients with severe active CD, and
adalimumab as a monotherapy treatment for the long-term
maintenance of both a remission of CD and the healing of
fistulas. Our main message is that the combination of ada-
limumab therapy and a standardized management protocol
for ECF can result in a good patient outcome in cases of
FCD. Nevertheless, larger studies focusing on the evalua-
tion of adalimumab treatment in patients with FCD, espe-
cially patients who develop spontaneous or post-operative
ECF, are needed to expand on the present experience of
treatment in this sub-population of CD.
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